阴道孕酮用于有早产史女性预防早产而不论宫颈长度:反对使用的论证
本文反对在有自发性早产史的单胎妊娠女性中普遍使用阴道孕酮预防复发性早产。近期低偏倚风险、预注册的大样本随机对照试验的Meta分析显示,阴道孕酮未显著降低复发性早产率;而报告获益的研究样本量较小、偏倚风险与选择性结局报告风险较高、外部效度低。美国食品药品管理局已撤销17α-羟孕酮己酸酯的批准。
要点
- 低偏倚风险、预注册的大样本随机对照试验的Meta分析显示,有自发性早产史的单胎妊娠女性补充阴道孕酮未显著降低复发性早产率。
- 报告阴道孕酮获益的研究样本量较小、偏倚风险与选择性结局报告风险较高、外部效度低。
- 作者据此反对普遍使用阴道孕酮预防复发性早产。
核心结论
- 作者反对在有早产史女性中普遍使用阴道孕酮补充以预防复发性早产。
研究设计与样本
- 本文为反对阴道孕酮普遍使用的论证性文章,引用近期预注册、低偏倚风险、低选择性结局报告风险的随机对照试验的Meta分析。
主要发现
- 近期Meta分析显示,在有自发性早产史的单胎妊娠女性中,阴道孕酮补充未显著降低复发性早产率。
- 报告阴道孕酮获益的研究样本量较小、偏倚风险与选择性结局报告风险较高、外部效度低。
- 美国食品药品管理局因疗效有限的数据撤销了17α-羟孕酮己酸酯的批准。
临床怎么用
- 作者反对普遍使用阴道孕酮补充预防复发性早产。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preterm birth, defined as birth before 37 weeks of gestation, has a significant public health effect as the most frequent cause of neonatal-related death and the second most frequent cause of infant-related death at the age of <5 years. Given the unclear and likely multifactorial etiologic nature of preterm birth, interventions to address this condition remain elusive. Progesterone supplementation was once considered a promising strategy for reducing preterm birth among patients with a history of previous preterm birth. However, more recent data suggesting limited efficacy led the United States Food and Drug Administration to revoke approval of 17-alpha hydroxyprogesterone caproate. Vaginal progesterone supplementation remains controversial. Recently published meta-analyses evaluating large, preregistered randomized controlled trials with low risk of bias and selective outcome reporting have found that recurrent preterm birth rates are not significantly reduced by vaginal progesterone supplementation in patients with a singleton pregnancy and previous history of spontaneous preterm birth. Furthermore, studies reporting any benefit from vaginal progesterone in this patient population are noted to have smaller sample sizes, higher risk of bias and selective outcome reporting, and low external validity. Therefore, our study argues against the universal use of vaginal progesterone supplementation for the prevention of recurrent preterm birth.
引用
- Torres AM, Wheeler S. Vaginal progesterone for prevention of preterm birth in women with a history of preterm birth regardless of cervical length: an argument against use. Am J Obstet Gynecol MFM. 2024. PMID: 39603525. doi:10.1016/j.ajogmf.2024.101571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。